A Practical Approach, Second Edition=Ronald D. Ho.pdf

54 DEVELOPMENTAL REPRODUCTIVE TOXICOLOGY: A PRACTICAL APPROACH, SECOND EDITION170. Minsker, D.H., MacDonald, J.S., Robertson, R.T., and Bokelman, D.L., Mevalonate supplementationin pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, Teratology, 28, 449, 1983.171. Brewer, L.M., Sheardown, S.A., and Brown, N.A., HMG-CoA reductase mRNA in the post-implantationrat embryo studied by in situ hybridization, Teratology, 47, 137, 1993.172. Krakoff, I., Brown, N., and Reichard, P., Inhibition of ribonucleoside diphosphate reductase byhydroxyurea, Cancer Res., 28, 1559, 1968.173. Chaube, S. and Murhph, M.L., Protective effect of deoxycytidylic acid (CdMP) on hydrosyureainducedmalformations in rats, Teratoloy, 7, 79, 1973.174. Herken, R., Merker, H.J., and Krowke, R., Investigation of the effect of hydroxyurea on the cell cycleand the development of necrosis in the embryonic CNS of mice, Teratology, 18, 103, 1978.175. Herken, R., The influence of deoxycytidine monophosphate (cDMP) on the cytotoxicity of hydroxyureain the embryonic spinal cord of the mouse, Teratology, 30, 83, 1984.176. Wawra, E., Microinjected deoxynucleotides for the study of chemical inhibition of DNA synthesis,Nucleic Acids Res., 16, 5249, 1988.177. DeSesso, J.M. and Goeringer, G.C., Ethoxyquin and nordihydroguaiaretic acid reduce hydroxyureadevelopmental toxicity, Reprod. Toxicol., 4, 267, 1990.178. DeSesso, J.M., Amelioration of teratogenesis. I. Modification of hydroxyurea-induced teratogenesisby the antioxidant propyl gallate, Teratology, 24, 19, 1981.179. Kessel, D. and Shurin, S.B., Transport of two non-metabolized nucleosides, deoxycytidine and cytosinearabinoside, in a sub-line of the L1210 murine leukemia, Biochim. Biophys. Acta, 163, 179, 1968.180. Kochhar, D.M., Penner, J.D., and McDay, J.A., Limb development in mouse embryos., Teratology,18, 71, 1978.181. Bhuyan, B.K., Scheidt, L.G., and Fraser, T.J., Cell cycle phase specificity of antitumor agents, CancerRes., 32, 398, 1972.182. Kochhar, D.M. and Agnish, N.D., “Chemical surgery” as an approach to study morphogenetic eventsin embryonic mouse limb, Develop. Biol., 61, 388, 1977.183. Zittoun, J., Marquet, J., David, J.C., Maniey, D., and Zittoun, R., A study of the mechanisms ofcytotoxicity of Ara-C on three human leukemic cell lines, Cancer Chemother. Pharmacol., 24, 251,1989.184. Chaube, S., Kreis, W., Uchida, K., and Murphy, M.L., The teratogenic effect of 1--D- arabinofuranosylcytosinein the rat, Biochem. Pharmacol., 17, 1213, 1968.185. Faustman, E.M. and Goodman, J.I., Alkylation of DNA in specific hepatic chromatin fractionsfollowing exposure to methylnitrosourea or dimethylnitrosamine, Toxicol. Appl. Pharmacol., 58, 379,1981.186. Ohgaki, H., Eibl, R.H., Wiestler, O.D., Yasargil, M.G., Newcomb, E.W., and Kleihues, P., p53mutations in nonastrocytic human brain tumors, Cancer Res., 51, 6202, 1991.187. Bochert, G., Platzek, T., Rahm, U., and Neubert, D., Embryotoxicity induced by alkylating agents:6. DNA adduct formation induced by methylnitrosourea in mouse embryos, Arch. Toxicol., 65, 390,1991.188. Kidney, J. and Faustman, E., Modulation of nitrosourea toxicity in rodent embryonic cells by O 6– benzylguanine,a depletor of O 6 -methylguanine-DNA methyltransferase, Toxicol. Appl. Pharmacol., 133,1, 1995.189. Francis, B.M., Rogers, J.M., Sulik, K.K., Alles, A.J., Elstein, K.H., Zucker, R.M., et al., Cyclophosphamideteratogenesis: evidence for compensatory responses to induced cellular toxicity, Teratology,42, 473, 1990.190. Gebhardt, D.O., The embryolethal and teratogenic effects of cyclophosphamide on mouse embryos,Teratology, 3, 273, 1970.191. Gibson, J.E. and Becker, B.A., The teratogenicity of cyclophosphamide in mice, Cancer Res., 28,475, 1968.192. Mirkes, P.E., Fantel, A.G., Greenaway, J.C., and Shepard, T.H., Teratogenicity of cyclophosphamidemetabolites: phosphoramide mustard, acrolein, and 4-ketocyclophosphamide in rat embryos culturedin vitro, Toxicol. Appl. Pharmacol., 58, 322, 1981.© 2006 by Taylor & Francis Group, LLC